CHEK1 and melanoma: Taken together, combinatorial treatments with PLX4032 and PF477736 reduce the levels of total Chk1 protein and Chk1 phosphorylation at S280 and S296, but increases the levels of Chk1 phosphorylation at S317 and S345 in both PLX4032 sensitive and resistant melanoma cells.